Brief: Labcorp Sees Total Labcorp Enterprise Revenue Up 1.0% - 4.0% For FY 2023

Laboratory of America Holdings

16/02/2023 12:22

Feb 16 (Reuters) - Laboratory Corporation Of America
Holdings  LH.N :
    * LABCORP SEES TOTAL LABCORP ENTERPRISE REVENUE UP 1.0% -
4.0% FOR
FY 2023 
    * LABCORP ANNOUNCES 2022 FOURTH QUARTER AND FULL-YEAR
RESULTS
    * LABCORP SEES FULL-YEAR 2023 GUIDANCE ADJUSTED EPS OF
$16.00 TO
$18.00 AND FREE CASH FLOW OF $1.0 BILLION TO $1.2 BILLION
    * LABCORP - DIAGNOSTICS REVENUE FOR QUARTER WAS $2.29
BILLION, A
DECREASE OF 12.8% FROM $2.62 BILLION IN Q4 OF 2021
    * LABCORP - DRUG DEVELOPMENT REVENUE FOR QUARTER WAS $1.39
BILLION, A DECREASE OF 4.1% FROM $1.45 BILLION IN Q4 OF 2021
    * LABCORP - GUIDANCE ASSUMES THAT CLINICAL DEVELOPMENT
BUSINESS
WILL BE WITH LABCORP FOR FULL YEAR
    * Q4 EARNINGS PER SHARE VIEW $4.10, REVENUE VIEW $3.74
BILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID: 
Further company coverage:  LH.N 
 ((Reuters.Briefs@thomsonreuters.com;))